Clinical Trial Equipment & Ancillary Solutions Market Size, Share & Trends Analysis Report By Product (Sourcing, Supply/Logistics), By Phase (Phase I, II, III), By Region (APAC, North America), And Segment Forecasts, 2023 - 2030

Report Overview

The global clinical trial equipment & ancillary solutions market size was valued at USD 2.7 billion in 2022 and is anticipated to exhibit a compound annual growth rate (CAGR) of 8.1% from 2023 to 2030. The global market has noticed critical growth on account of the rising R&D investments, evolving need for clinical trials, and the rapid growth of the pharmaceutical and medical industries. The COVID-19 outbreak temporarily slowed down the process of clinical trials in 2020, owing to the national lockdown implemented by the government, which had affected the market negatively. However, the growing demand for an effective treatment for COVID-19 and other diseases improves the number of trials post covid. For instance, according to ClinicalTrial.Gov, 325,761 studies were reported in 2020, whereas in 2022 the number of studies reached 399502 by 2023. The surge in clinical studies is expected to support the market post-pandemic.

As clinical trials evolve, more resources are required for a clinical trial, including the drugs, equipment, and ancillary supplies. Ancillary supplies include all items necessary to perform a clinical study, such as syringes, surgical knives, swabs, gloves, and any other material that the patient and medical professional need to administer the medication and analyze the effectiveness and safety parameters under examination.

Sourcing equipment & ancillary materials for clinical trials involves considerably more than just procurement. It needs an in-depth understanding of the study’s design and requirements, as well as rigorous proactive planning to guarantee that the most relevant equipment and supplies are bought at the correct time and at a reasonable price. A combination of internal knowledge and external help is strongly recommended in handling the complexity of equipment and ancillary supply, restocking, logistics, and expiry management.

There is a massive rise in the number of clinical studies being undertaken for COVID-19, and this is expected to improve market growth. Apart from this high investment in R&D and adoption of virtual clinical trials owing to the pandemic have further supported the market growth.

Product Insights

The supply/logistics segment dominated the market and accounted for the largest revenue share of 38.8% in 2022. As clinical trials have become more global and diverse, they require a proper cold chain logistics system to maintain the integrity of temperature-sensitive drugs. Fluctuation in rules & regulations in emerging markets is expected to boost the need for supply/logistic services during the forecast period.

The sourcing segment on the other hand is anticipated to witness a considerable growth rate of 7.9% across the forecast period. Due to the increasing complexity of clinical trials, the quantity of equipment and ancillary supplies required, as well as the number of diverse suppliers required to supply them, has increased substantially. The challenge of ensuring that supplies reach sites in a cost-effective manner for worldwide research has increased. With sourcing and distribution expertise, there is a single point of contact to supply and transport equipment and ancillary supplies all over the world. This streamlined and coordinated procedure removes the strain on both clinical trial teams and facilities.

Phase Insights

The phase III segment accounted for the maximum revenue share of the global market of 54.1% in 2022. The segment is likely to remain dominant even during the forecast years. Clinical studies in phase III are more complicated than those in earlier stages. Even though the number of medicines in this phase is relatively minimal, the complications associated with this phase are the largest.

In addition, the failure rate is also highest in this phase as the sample size and research design need precise dosing at an optimal level. The failure causes both human and financial damage, and most failures are caused by non-compliance with safety requirements. Such a scenario is likely to increase the demand for effective supply chain and logistics, which is projected to boost market growth over the coming years.

The phase I segment is poised to witness significant growth across the forecast period due to the increasing number of pharmaceutical companies focusing on developing novel therapeutics for rare diseases. Growth in the number of CROs across the world is another factor supporting the adoption of phase I clinical trials to boost the rapid development of drugs.

Regional Insights

North America dominated the global clinical trial equipment & ancillary solutions market in 2022 with the largest revenue share of 40.4%. This is attributed to the fact that most pharmaceutical businesses are located in the U.S. and perform most of their business in this region. Favorable regulatory policies, the introduction of technologically advanced products by the market players, and increasing investments by pharmaceutical firms are expected to drive regional market growth during the forecast period.

Asia Pacific is projected to be the fastest-growing regional market with a CAGR of 9.5% during the forecast period. The Asia Pacific region has become a hotspot for conducting clinical trials on account of the ease of regulatory compliance, cheap study costs, a growing patient population, and the existence of a few elite clinical institutions functioning as sites.

Key Companies & Market Share Insights

Mergers, acquisitions, expansions, and collaborations, are the key strategies adopted by key players to maintain their market share. For instance, in September 2021, Ancillare acquired NG BV in the Netherlands. The acquisition strengthens Ancillare's supply chain capabilities in the pharmaceutical products area, offering sponsors worldwide greater control and supply chain transparency. In July 2021, Parexel announced an inventive collaboration with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to design patient-centric protocol designs and methodologies for decentralized clinical trials in China. This will also involve quantitative research to enhance the clinical trial experience of oncology patients. Some prominent players in the global clinical trial equipment & ancillary solutions market are:

• Ancillare, LP

• Imperial CRS

• Woodley Equipment Company Ltd.

• Thermo Fisher Scientific, Inc.

• PAREXEL International Corp.

• Emsere (Medicapital Rent)

• Quipment SAS

• IRM

• Marken A UPS Company

• Myonex

• Yourway

Clinical Trial Equipment & Ancillary Solutions Market Report Scope

Global Clinical Trial Equipment & Ancillary Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global clinical trial equipment & ancillary solutions market based on product, phase, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Sourcing

    • Procurement

      • Equipment

      • Ancillaries

    • Rental

      • Equipment

      • Ancillaries

  • Supply/Logistics

    • Transportation

    • Packaging

    • Others

  • Service

    • Calibrations

    • Equipment Servicing

    • Others

  • Others

• Phase Outlook (Revenue, USD Million, 2018 - 2030)

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait